首页 | 本学科首页   官方微博 | 高级检索  
检索        


Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
Authors:Shan-Shan Qi  Jia-Hui Sun  Hao-Han Yu
Institution:1. Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, The People’s Republic of China;2. Cancer Pharmacology Crown Bioscience Inc, Taicang, The People’s Republic of China;3. Nanjing DeBioChem Inc, Nanjing, The People’s Republic of China
Abstract:To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development.
Keywords:Combination chemotherapy  nano drug co-delivery system (NDCDS)  multidrug resistance (MDR)  targeting nanoparticles  drug delivery materials
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号